- Home
- RDI vs ANTX Comparison
RDI vs ANTX Comparison
Compare RDI & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- ANTX
- Stock Information
- Founded
- RDI 1937
- ANTX 2017
- Country
- RDI United States
- ANTX United States
- Employees
- RDI N/A
- ANTX N/A
- Industry
- RDI Movies/Entertainment
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- ANTX Health Care
- Exchange
- RDI Nasdaq
- ANTX Nasdaq
- Market Cap
- RDI 27.9M
- ANTX 33.2M
- IPO Year
- RDI N/A
- ANTX 2022
- Fundamental
- Price
- RDI $1.34
- ANTX $1.05
- Analyst Decision
- RDI Hold
- ANTX Buy
- Analyst Count
- RDI 1
- ANTX 2
- Target Price
- RDI $2.40
- ANTX $2.00
- AVG Volume (30 Days)
- RDI 30.0K
- ANTX 257.5K
- Earning Date
- RDI 08-13-2025
- ANTX 08-12-2025
- Dividend Yield
- RDI N/A
- ANTX N/A
- EPS Growth
- RDI N/A
- ANTX N/A
- EPS
- RDI N/A
- ANTX N/A
- Revenue
- RDI $205,644,000.00
- ANTX N/A
- Revenue This Year
- RDI $7.47
- ANTX N/A
- Revenue Next Year
- RDI $13.22
- ANTX N/A
- P/E Ratio
- RDI N/A
- ANTX N/A
- Revenue Growth
- RDI N/A
- ANTX N/A
- 52 Week Low
- RDI $1.17
- ANTX $0.87
- 52 Week High
- RDI $1.89
- ANTX $3.07
- Technical
- Relative Strength Index (RSI)
- RDI 48.07
- ANTX 42.32
- Support Level
- RDI $1.24
- ANTX $1.05
- Resistance Level
- RDI $1.34
- ANTX $1.11
- Average True Range (ATR)
- RDI 0.06
- ANTX 0.04
- MACD
- RDI 0.00
- ANTX 0.00
- Stochastic Oscillator
- RDI 52.63
- ANTX 0.00
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.